Lemborexant for the Treatment of Residual Insomnia in Major Depressive Disorder (MDD)

NCT06843187 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Major Depressive Disorder(MDD)
Insomnia Comorbid to Psychiatric Disorder

Interventions

DRUG: Lemborexant
OTHER: Placebo

Sponsor

Unity Health Toronto

Collaborators

University of Toronto
Centre for Addiction and Mental Health
Toronto Metropolitan University